Purpose of the study: to study the efficacy and safety of Ranibizumab in patients with pathologic myopia and choroidal neovascularization (CNV).22patients (22eyes) with myopic CNV were included in the study. Mean age was 54.0±14.4years, axial length – 28.25±1.9mm, follow-up – from 12 to 59months (mean follow-up – 26.9±13.8months). Ranibizumab was administered intravitreally according to the label in patients with active CNV confirmed by fluorescein angiography. The treatment was shown to have favorable early and long-term outcomes. For example, visual acuity increased (from 0.25 to 0.54; p<0.01), central retinal thickness decreased (from 335.8 to 273.25μm; p<0,05), subretinal neovascular membrane area decreased (from 1272 to 969μm; p<0.05). Clinically significant treatment complications were not observed.Conclusions: The study confirmed high efficacy and safety of anti-angiogenic therapy.
pathologic myopia, Ranibizumab, myopic choroidal neovascularization, compliance
1. BoykoEV, SosnovskiySV, BerezinRD, DavydovaVV, SmirnovIN (2009). Defining tactics of anti-VEGF treatment of myopic choroidal neovascularization [Opredelenie taktiki anti-VEGF terapii miopicheskoy khorioidal’noy neovaskulyarizatsii]. Rol’ i mesto farmakoterapii v sovremennoy oftal’mologicheskoy praktike: tezisy dokladov Vserossiyskoy nauchnoy konferentsii s mezhdunarodnym uchastiem, 58-61.
2. LibmanES, TolmachevRA, ShakhovaEV (2006). Epidemiological characteristics of disability due to the basic forms of maculopathy [Epidemiologicheskie kharakteristiki invalidnosti vsledstvie osnovnykh form makulopatiy]. Tezisy dokladov Vserossiyskogo seminara «Kruglyy stol «Makula-2006», 15-21.
3. KorotkikhSA, MikheevaEG, YablonskayaLY, KolesnikovaEI, KnyazevaES, ZalesovaVV, StepanovaEA, ZhdanovaNK, GvozdevaDA, BobykinEV (2013). Medical-social examination in the pathology of the organ of vision, specialized ophthalmological centers of the Sverdlovsk region [Mediko-sotsial’naya ekspertiza pri patologii organa zreniya, spetsializirovannye oftal’mologicheskie tsentry Sverdlovskoy oblasti]. Aktual’nye problemy oftal’mologii – 2013: sbornik materialov nauchno-prakticheskoy konferentsii oftal’mologov UrFO, 14-15
4. BresslerNM (2001). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – TAP report 2. Arch. Ophthalm., (119), 198-207
5. CohenSY, LarocheA. LeguenY, SoubraneG, CoscasGJ (1996). Etiology of choroidal neovascularization in young patients. Ophthalmology, (103), 1241-1244.
6. WongTY, Ohno-MatsuiK, LevezielN, HolzFG,LaiTY, YuHG, LanzettaP, ChenY, TufailA (2015). Myopic choroidal neovascularisation: current concepts and update on clinical management. Br. J. Ophthalm., 99(3), 289-296, doi: 10.1136/bjophthalmol-2014-305131.
7. WolfS, BalciunieneVJ, Laganovska G, MenchiniU, Ohno-MatsuiK, SharmaT, WongTY, SilvaR, PilzS, GekkievaM (2014). RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology, 121(3), 682-692
